PL4393545T3 - Nowe zastosowania pochodnych piperydynylo-indolowych - Google Patents

Nowe zastosowania pochodnych piperydynylo-indolowych

Info

Publication number
PL4393545T3
PL4393545T3 PL24170648.0T PL24170648T PL4393545T3 PL 4393545 T3 PL4393545 T3 PL 4393545T3 PL 24170648 T PL24170648 T PL 24170648T PL 4393545 T3 PL4393545 T3 PL 4393545T3
Authority
PL
Poland
Prior art keywords
piperidinyl
new applications
indole derivatives
indole
derivatives
Prior art date
Application number
PL24170648.0T
Other languages
English (en)
Inventor
Jörg EDER
Richard Alexander Harrison
Boerje Haraldsson
Anna Svenja Schubart
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PL4393545T3 publication Critical patent/PL4393545T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
PL24170648.0T 2017-08-31 2018-08-30 Nowe zastosowania pochodnych piperydynylo-indolowych PL4393545T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP17188870 2017-08-31

Publications (1)

Publication Number Publication Date
PL4393545T3 true PL4393545T3 (pl) 2026-03-16

Family

ID=59745840

Family Applications (2)

Application Number Title Priority Date Filing Date
PL24170648.0T PL4393545T3 (pl) 2017-08-31 2018-08-30 Nowe zastosowania pochodnych piperydynylo-indolowych
PL18769510.1T PL3675854T3 (pl) 2017-08-31 2018-08-30 Pochodne piperydynyloindolu do zastosowania w leczeniu glomerulopatii c3

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL18769510.1T PL3675854T3 (pl) 2017-08-31 2018-08-30 Pochodne piperydynyloindolu do zastosowania w leczeniu glomerulopatii c3

Country Status (22)

Country Link
US (3) US11723901B2 (pl)
EP (3) EP4647121A3 (pl)
JP (3) JP6754919B1 (pl)
KR (3) KR102497487B1 (pl)
CN (5) CN117338782A (pl)
AU (1) AU2018326768B2 (pl)
BR (1) BR112020003737A2 (pl)
CA (1) CA3073346A1 (pl)
CL (1) CL2020000483A1 (pl)
DK (2) DK3675854T3 (pl)
ES (2) ES3022885T3 (pl)
FI (2) FI3675854T3 (pl)
HR (2) HRP20250386T1 (pl)
HU (1) HUE071118T2 (pl)
IL (1) IL272888B2 (pl)
LT (2) LT3675854T (pl)
MX (3) MX2020002185A (pl)
PL (2) PL4393545T3 (pl)
PT (2) PT4393545T (pl)
RS (2) RS66635B1 (pl)
SI (2) SI4393545T1 (pl)
WO (1) WO2019043609A1 (pl)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112020003737A2 (pt) 2017-08-31 2020-09-01 Novartis Ag usos de derivados de piperidinil-indol
US20230064254A1 (en) * 2019-12-19 2023-03-02 Taiho Pharmaceutical Co., Ltd. Therapeutic agent containing fused pyrimidine compound as active ingredient
WO2021234544A1 (en) 2020-05-18 2021-11-25 Novartis Ag Crystalline form of lnp023
WO2022028507A1 (zh) 2020-08-07 2022-02-10 上海美悦生物科技发展有限公司 一种杂环类化合物、其制备方法及用途
WO2022028527A1 (zh) * 2020-08-07 2022-02-10 上海美悦生物科技发展有限公司 补体因子b抑制剂及其药物组合物、制备方法和用途
CN116583508B (zh) * 2020-12-30 2025-05-23 浙江星浩澎博医药有限公司 一系列哌啶取代的苯酸类化合物及其应用
MX2023007853A (es) 2020-12-30 2023-07-07 Jiangsu Hengrui Pharmaceuticals Co Ltd Compuesto heterociclico puenteado que contiene nitrogeno, metodo de preparacion y uso medico del mismo.
MX2023013148A (es) * 2021-05-07 2023-11-28 Novartis Ag Iptacopan para el tratamiento del sindrome uremico hemolitico atipico.
JP2024532847A (ja) * 2021-08-18 2024-09-10 シーザン ハイスーク ファーマシューティカル カンパニー リミテッド ベンズアゼピン芳香環誘導体及びその医薬的な応用
CA3236104A1 (en) * 2021-10-27 2023-05-04 Hugh Y. Zhu Piperidinyl indole derivatives, preparation methods and medicinal uses thereof
PE20242005A1 (es) * 2022-01-24 2024-10-03 Novartis Ag Derivados espirociclicos de piperidinilo como inhibidores del factor b del complemento y usos de los mismos
EP4471021A4 (en) * 2022-01-26 2025-04-30 Shanghai Meiyue Biotech Development Co., Ltd. Salt type and crystal form of complement factor b inhibitor, and preparation method therefor and application thereof
CN119343347A (zh) * 2022-06-10 2025-01-21 正大天晴药业集团股份有限公司 双环取代的芳香羧酸酯类化合物
WO2023246677A1 (zh) * 2022-06-20 2023-12-28 深圳信立泰药业股份有限公司 一种吲哚-苯基哌啶化合物及其制备方法与应用
WO2024002353A1 (zh) 2022-06-30 2024-01-04 江苏恒瑞医药股份有限公司 一种含氮桥杂环衍生物的可药用盐、晶型及其制备方法
CA3266935A1 (en) * 2022-09-10 2024-03-14 Jiangsu Hansoh Pharmaceutical Group Co., Ltd. Piperidine derivatives substituted at position 2, their preparation methods and medicinal uses
CN118026998A (zh) 2022-11-11 2024-05-14 上海医药工业研究院有限公司 哌啶取代的苯甲酸类化合物、其药物组合物和应用
WO2024141011A1 (zh) * 2022-12-31 2024-07-04 深圳晶泰科技有限公司 补体因子b抑制剂及其药物组合物和应用
CN119371402A (zh) 2023-07-26 2025-01-28 上海美悦生物科技发展有限公司 螺环烯基类或氮杂烯基类化合物及其药物组合物、制备方法和用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8192742B2 (en) * 2007-03-23 2012-06-05 NovelMed Therapeutics Method of inhibiting complement activation with human anti-factor C3 antibodies and use thereof
US9487483B2 (en) 2012-06-28 2016-11-08 Novartis Ag Complement pathway modulators and uses thereof
US9475806B2 (en) * 2013-03-14 2016-10-25 Novartis Ag Complement factor B inhibitors and uses there of
JO3425B1 (ar) 2013-07-15 2019-10-20 Novartis Ag مشتقات البابيريدينيل-اندول واستخدامها كعامل متمم لمثبطات b
US10640540B2 (en) * 2015-12-23 2020-05-05 Greenovation Biotech Gmbh Polypeptides for inhibiting complement activation
CA3010593C (en) * 2016-01-05 2024-02-13 University Of Leicester Methods for inhibiting fibrosis in a subject in need thereof
BR112020003737A2 (pt) 2017-08-31 2020-09-01 Novartis Ag usos de derivados de piperidinil-indol
WO2021234544A1 (en) 2020-05-18 2021-11-25 Novartis Ag Crystalline form of lnp023
US11951101B2 (en) 2020-07-16 2024-04-09 Novartis Ag Methods of using factor B inhibitors

Also Published As

Publication number Publication date
US11723901B2 (en) 2023-08-15
MX2020002185A (es) 2020-07-14
HRP20250386T1 (hr) 2025-05-23
DK3675854T3 (da) 2025-04-07
KR102497487B1 (ko) 2023-02-08
EP4647121A3 (en) 2026-02-18
PL3675854T3 (pl) 2025-05-19
LT4393545T (lt) 2026-01-12
US20250195493A1 (en) 2025-06-19
HRP20251596T1 (hr) 2026-01-30
JP2020529466A (ja) 2020-10-08
BR112020003737A2 (pt) 2020-09-01
US20200338059A1 (en) 2020-10-29
CN117338782A (zh) 2024-01-05
RU2020111788A3 (pl) 2021-12-28
IL272888A (en) 2020-04-30
CN117398384A (zh) 2024-01-16
KR20240111007A (ko) 2024-07-16
EP4393545B1 (en) 2025-10-08
KR102682887B1 (ko) 2024-07-08
CN117338781A (zh) 2024-01-05
AU2018326768B2 (en) 2021-07-29
MX2023010751A (es) 2023-09-20
DK4393545T3 (da) 2026-01-12
FI3675854T3 (fi) 2025-04-07
ES3058507T3 (en) 2026-03-11
JP2020193222A (ja) 2020-12-03
JP2021181471A (ja) 2021-11-25
EP3675854A1 (en) 2020-07-08
ES3022885T3 (en) 2025-05-29
IL272888B1 (en) 2023-09-01
CN111032042A (zh) 2020-04-17
SI3675854T1 (sl) 2025-05-30
MX2023010750A (es) 2023-09-20
EP4393545A3 (en) 2024-09-25
EP4393545A2 (en) 2024-07-03
FI4393545T3 (fi) 2026-01-14
LT3675854T (lt) 2025-04-25
KR20230024432A (ko) 2023-02-20
EP4647121A2 (en) 2025-11-12
IL272888B2 (en) 2024-01-01
HUE071118T2 (hu) 2025-08-28
PT4393545T (pt) 2025-12-23
CN117338783A (zh) 2024-01-05
AU2018326768A1 (en) 2020-02-06
US12285422B2 (en) 2025-04-29
EP3675854B1 (en) 2025-01-22
WO2019043609A1 (en) 2019-03-07
JP6929425B2 (ja) 2021-09-01
SI4393545T1 (sl) 2026-02-27
CL2020000483A1 (es) 2020-09-04
PT3675854T (pt) 2025-04-04
RS66635B1 (sr) 2025-04-30
JP6754919B1 (ja) 2020-09-16
US20220152011A1 (en) 2022-05-19
KR20200047540A (ko) 2020-05-07
CA3073346A1 (en) 2019-03-07
RS67530B1 (sr) 2026-01-30
JP7297016B2 (ja) 2023-06-23
RU2020111788A (ru) 2021-09-30

Similar Documents

Publication Publication Date Title
PL4393545T3 (pl) Nowe zastosowania pochodnych piperydynylo-indolowych
PT3645518T (pt) Síntese de omecamtiv mecarbil
IL268731A (en) New uses of anti-sirpg antibodies
PL3457851T3 (pl) Pochodne sobetiromu
IL272851A (en) Methods of using dipivefrin
IL254502A0 (en) Solid forms of menaquinols
HRP20251697T1 (hr) Kristalni oblik n-butildeoksigalaktonojirimicina
EP3727126A4 (en) MULTI-PURPOSE SCOPE
LT3652187T (lt) Patobulintas imetelstato gamybos būdas
DK3625231T3 (da) Derivatives of resiquimod
PL3350308T3 (pl) Zastosowanie włókna liocelowego
IT201700010606A1 (it) GenialCombi di Moscarelli
IT201700068126A1 (it) Struttura di filtropressa
UA36785S (uk) Комплект етикеток
UA36511S (uk) Комплект етикеток
UA36777S (uk) Комплект етикеток
UA36757S (uk) Комплект етикеток
UA36378S (uk) Комплект етикеток
UA36367S (uk) Комплект етикеток
UA36364S (uk) Комплект етикеток
UA36348S (uk) Комплект етикеток
UA36405S (uk) Комплект етикеток
UA36329S (uk) Комплект етикеток
UA36324S (uk) Комплект етикеток
UA35783S (uk) Комплект етикеток